Research programme: CD200-based therapeutics - Trillium Therapeutics Inc
Alternative Names: Anti-CD 200 monoclonal antibodies; CD200 fusion protein; CD200Fc; TTI 200.7Latest Information Update: 29 Nov 2021
At a glance
- Originator Trillium Therapeutics Inc
- Class Monoclonal antibodies; Proteins
- Mechanism of Action CD200 antigen inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Immunological disorders; Transplant rejection